Study of Intravenously Administered SNS-032 in Patients With Advanced B-lymphoid Malignancies
Status:
Completed
Trial end date:
2009-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety and tolerability of escalating doses of
SNS-032, given in 3 weekly administrations per cycle and to identify a recommended Phase 2
dose.